

1 **A Cross-Sectional Analysis of Syncytiotrophoblast Membrane Extracellular Vesicles**
2 **Derived Transcriptomic Biomarkers in Preeclampsia.**

3 Toluwalase AWOYEMI DPhil^{1*}, Wei ZHANG PhD^{1*}, Maryam RAHBAR DPhil¹, Adam
4 CRIBBS PhD², Prasanna LOGENTHIRAN MB;BS¹, Shuhan JIANG DPhil¹, Gavin COLLETT
5 PhD¹, Ana Sofia CERDEIRA PhD¹ & Manu VATISH DPhil^{1,3}

6

7

8 * Equal Contribution

9 1 Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford,
10 United Kingdom.

11 2 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
12 University of Oxford, Oxford, United Kingdom.

13 3. Welcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.

14

15

16

17 ***Corresponding author:** Dr Manu Vatish, MBBCh, BA (Hons), DPhil, MA, FMRCOG

18 Manu.vatish@wrh.ox.ac.uk, Phone number- +441865221009, Fax number-01865769141

19 Address: Nuffield Department of Women's and Reproductive Health, University of Oxford,
20 Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom

21 **Abstract**

22 **Background:** Preeclampsia (PE) is a pregnancy-specific hypertensive disorder affecting 2-8% of
23 pregnancies worldwide. Biomarker(s) for PE exists, but while these have excellent negative
24 predictive value, their positive predictive value is poor. Extracellular vesicles released by the
25 placenta into the maternal circulation, syncytiotrophoblast membrane extracellular vesicles -
26 STB-EVs- have been identified as being involved in PE with the potential to act as liquid
27 biopsies. **Objective:** To identify differences in STB-EV and placenta transcriptome between PE
28 and normal pregnancy (NP).

29 **Methods:** We performed RNA-sequencing (RNA-seq) on placental tissue, medium/large and
30 small STB-EVs from PE (n=6) and NP (n=6), followed by bioinformatic analysis to identify
31 targets that could be used in the future for EV-based diagnostic tests for preeclampsia. Some of
32 the identified biomarkers were validated with real-time polymerase chain reactions.

33 **Results:** Our analysis identified and verified the differential expression of FLNB, COL17A1,
34 SLC45A4, LEP, HTRA4, PAPP-A2, EBI3, HSD17B1, FSTL3, INHBA, SIGLEC6, and CGB3.
35 Our analysis also identified interesting mechanistic processes via an in-silico prediction of STB-
36 EV-based mechanistic pathways.

37 **Conclusions:** In this study, we identified potential biomarkers and mechanistic gene pathways
38 that may be important in the pathophysiology of PE and could be further explored in future
39 studies.

40 **Funding:** This research was funded by the Medical Research Council (MRC Programme Grant
41 (MR/J0033601) and the Medical & Life Sciences translational fund (BRR00142 HE01.01)

42 **Keywords:** Transcriptomics, Syncytiotrophoblast membrane extracellular vesicles (STB-EVs),
43 Preeclampsia, Biomarkers, Placenta EVs, mechanisms.

44

45 **Introduction**

46 Preeclampsia (PE) is a multisystemic hypertensive disorder that affects approximately 2-8% of
47 pregnancies worldwide (Lisonkova & Joseph, 2013). It is a pregnancy-specific complication which
48 results in hypertension (systolic blood pressure ≥ 140 mmHg / diastolic pressure ≥ 90 mmHg) and
49 proteinuria (protein/creatinine ratio of ≥ 30 mg/mmol or more), or evidence of maternal acute
50 kidney injury, liver dysfunction, neurological abnormalities, hemolysis, thrombocytopenia,
51 and/or fetal growth restriction and in severe cases, death(Brown et al., 2018). Preeclampsia in
52 particular, early onset preeclampsia (EOPE) has been referred to as a two-stage process, starting
53 with mal-placentation which results in syncytiotrophoblast stress (stage 1) and ending in
54 maternal end-organ damage (stage 2)(C. W. G. Redman et al., 2022). However, the direct cause
55 of PE (i.e., mechanisms of placental dysfunction) is still under study, with the only available
56 treatment being the delivery of the placenta (C. Redman, 2014).

57 Syncytiotrophoblast membrane extracellular vesicles (STB-EVs) are lipid bilayer spherical
58 structures of placental origin which can be classified based on their size and biogenesis pathways
59 into medium/large and small STB-EVs (Yáñez-Mó et al., 2015). Small STB-EVs are less than or
60 equal to 200 nm in size and formed through multivesicular bodies, whereas medium/large EVs
61 are between 201 nm to 1000 nm and released directly through the budding of the plasma
62 membrane (Théry et al., 2018). Their cargo consists of surface proteins, encapsulated proteins,
63 and different subclasses of RNAs such as long noncoding RNAs, messenger RNAs, transfer
64 RNAs, and micro RNAs (Colombo et al., 2014), which may be released into target cells through
65 fusion of STB-EVs with distant cells. This ability of STB-EVs further implicates them as
66 potential pathogenic factors in PE. However, the transcriptome of the subtypes of STB-EVs has

67 not been thoroughly explored. Previous studies have identified differentially expressed genes
68 (DEGs) from PE placental tissue such as *Sialic acid-binding Ig-like lectin 6 (SIGLEC6)*,
69 *Vascular endothelial growth factor receptor 1(VEGFR1)*, *Adrenomedullin (ADM)*, and
70 *Pappalysin-2 (PAPP-A2)* (Rumer et al., 2013; Tsai et al., 2011a), *Basic Helix-Loop-Helix Family*
71 *Member E40 (BHLHE40)*, *Divergent-Paired Related Homeobox (DPRX)*, and *HtrA Serine*
72 *Peptidase 4 (HTRA4)* (Ren et al., 2021) compared to normal placental tissue. However, none to
73 the best of our knowledge have explored this in the context of STB-EVs between PE and normal
74 pregnancy (NP).

75 We hypothesized that 1) the transcriptome of the placental tissue and STB-EVs are different
76 between PE and NP and 2) analyzing these different sample sub-types would allow for more
77 comprehensive and holistic profiling. We believe this strategy increases the probability of
78 detecting relevant biomarkers and mechanistic pathways in PE. We performed RNA-sequencing
79 (RNA-seq) on placental tissue, medium/large and small STB-EVs from PE and NP. Our analysis
80 revealed novel biomarkers and new insights into possible mechanisms of preeclampsia. This
81 knowledge may help to inform future extracellular vesicle-based diagnostic tests, mechanistic
82 experiments and ultimately, the development of new therapies.

83 **Methods**

84 *Ethics approval and patient information*

85 We obtained ethical approval from the Central Oxfordshire Research Ethics Committee C (REFS
86 07/H0607/74 & 07/H0606/148). We obtained written informed consent from pregnant women
87 undergoing elective caesarean sections before labour onset at the Women's Centre, John
88 Radcliffe Hospital, Oxford. Placentas from normal (NP) n=12 and preeclamptic (PE) n=12

89 pregnancies were collected and perfused within ten minutes of delivery. We defined NP as
90 singleton pregnancy with no history of preeclampsia, hypertensive disorders, or other
91 complications in pregnancy. Patients with preeclampsia were defined as the co-occurrence of *de*
92 *novo* hypertension (blood pressure > 140/90 mmHg) and proteinuria (protein/creatinine ratio \geq
93 30 mg/mmol) and/or evidence of maternal acute kidney injury, liver dysfunction, neurological
94 abnormalities, hemolysis, thrombocytopenia, and/or fetal growth restriction after week twenty of
95 gestation according to the criteria of the International Society for the Study of Hypertension in
96 Pregnancy (Brown et al., 2018). All PE patients used in this study were of early onset PE
97 (diagnosed before 34 weeks gestation).

98 ***Enrichment of STB-EVs by placental dual-lobe perfusion and serial ultracentrifugation***

99 We have previously published our protocol of STB-EVs isolation through *ex vivo* dual lobe
100 placental perfusion (Dragovic et al., 2015). Briefly, we identified a suitable cotyledon (devoid of
101 calcifications, ischemia, or rupture) and cannulated a placental artery and vein perfusing the
102 placenta for three hours at a 4-5 ml/min flow rate to obtain placenta perfusate. The placenta
103 perfusate was centrifuged twice at 1,500 g for ten minutes at 4°C (*Beckman Coulter Avanti J-*
104 *20XP centrifuge using a Beckman Coulter JS-5.3 swing-out rotor*) to remove cell debris. The
105 supernatant was carefully pooled and spun at 10,000 g (10K) in a swing bucket centrifuge
106 (*Beckman L80 ultracentrifuge and Sorvall TST28.39 swing-out rotor*) at 4°C for 30 minutes.
107 The 10K STB-EV pellet was washed with filtered phosphate buffer saline (fPBS) followed by
108 resuspension of the 10K STB-EV pellets in fPBS. An aliquot of the resuspended pellets was
109 analysed to identify and characterise STB-EVs, while the rest were aliquoted to obtain a protein
110 concentration around 2-5 $\mu\text{g}/\mu\text{l}$ (measured using a Pierce bicinchoninic acid (BCA) protein
111 assay) and immediately stored at -80°C. The post-10K supernatant was filtered through a 0.22

112 μm Millipore stericup filtration device, then spun at 150,000 g for 2 hours (*Beckman L80*
113 *ultracentrifuge with a Sorvall TST28.39 swing-out rotor*) and the 150K STB-EV pellets were
114 washed, resuspended in fPBS and aliquoted like the 10K STB-EV pellets. This working stock
115 was used for subsequent analysis. Our STB-EV enrichment and categorization process has been
116 deposited on EV Track ([\[http://www.EVTRACK.org\]](http://www.EVTRACK.org), **EV-TRACK ID: EV210382**) with a
117 score of 78% correlating with excellent enrichment and categorization.

118 *Transmission electron microscopy*

119 STB-EV pellets were diluted with fPBS to achieve an STB-EV solution with concentrations
120 between 0.1-0.3 $\mu\text{g}/\mu\text{l}$. Ten microliter of the STB-EV pellet solution was applied to freshly
121 glowing discharged carbon formvar 300 mesh copper grids for two minutes, blotted with filter
122 paper, and stained with 2% uranyl acetate for ten seconds and air-dried. STB-EV pellets on the
123 grid were negatively stained to enhance the contrast between STB-EVs pellets and the
124 background. The grids were imaged using an FEI Tecnai 12 TEM at 120 kV with a Gatan
125 OneView CMOS camera.

126 *Flow Cytometry*

127 A BD LSRII flow cytometer (BD Biosciences) with a blue, violet, and red laser was used for all
128 sample analyses. Daily quality control (QC) was run using CS&T beads (BD Biosciences).
129 Photomultiplier tube (PMT) voltage determined by CS&T run was applied to all fluorescent
130 detectors with exception for the side scatter (SSC) which was determined by Apogee Mix (1493,
131 Apogee Flow System, UK). SSC PMT voltage that triggered 0.59 μm silica beads and above was
132 applied to all 10K STB-EV pellets and analyzed. An SSC threshold of 200 was applied to
133 remove background noise below 0.59 μm silica beads. A flow rate of 10 $\mu\text{l}/\text{min}$ was achieved

134 using the TruCount beads (BD science). For sample staining, 90 ml of 10K STB-EV pellet were
135 incubated with ten ml of Fc receptor blocker (Miltenyl, UK) for 10 minutes at 4°C and then
136 stained with phycoerythrin (PE) conjugated PLAP (for syncytiotrophoblast origin), PE Vio770
137 conjugated anti classical HLA class I and II (to exclude co-isolated non-placenta EVs and white
138 blood cell (WBC) EV co-isolation), Pacific blue conjugated CD41 (to identify co-isolated
139 platelet EVs) and CD235a (to identify co-isolated red blood cell (RBC) EVs) for ten minutes at
140 room temperature in the dark. Stained samples were transferred to an Ultra free 0.2 µm filter unit
141 (Millipore) and centrifuged at 800 g for three minutes to remove unbound antibodies and EVs
142 smaller than the filter pore size. Ninety microliters of fPBS were used to recover 10K STB-EVs
143 retained on the filter membrane. Recovered 10K STB-EVs were further stained with BODIPY
144 FL N-(2-aminoethyl)-maleimide [505/513 nm] (Molecular Probes) at a final concentration of 0.5
145 nM in the dark at room temperature for ten minutes before samples were diluted to 500 ml and
146 analyzed on the flow cytometer to check for events rate. When necessary, dilutions were made to
147 achieve an events rate of ≤ 400 count/second and to reduce swarming. 10K STB-EV pellets were
148 analyzed at 10 µl/minute for ten minutes and a total of 100 µl diluted samples was analyzed for
149 each sample. Fluorescence minus one (FMO-1) for each fluorochrome and stained samples re-
150 acquired after 2% Nonidet P-40 (NP-40) (Sigma) treatment were used as controls. Data and
151 figures generated were generated with the Flowjo software version 10 (Tree Star Inc., Ashland,
152 OR).

153 *Nanoparticle Tracking Analysis*

154 We further characterised the 10K and 150K STB-EV pellets by nanoparticle tracking analysis
155 [(NTA) NanoSight NS500 instrument equipped with a 405 nm laser (Malvern UK), sCMOS
156 camera and NTA software version 2.3, Build 0033 (Malvern UK)]. Before sample analysis,

157 instrument performance was checked with silica 100 nm microspheres (Polysciences, Inc.). The
158 10K and 150K STB-EV pellets were individually diluted in fPBS to a range of 1/100,000. The
159 samples were automatically injected into the sample chamber with a 1 ml syringe with the
160 following script used for EV measurements: prime, delay 5, capture 60, repeat 4. Images of the
161 analyzed samples were captured on camera at level 12 (Camera shutter speed; 15 milliseconds
162 and Camera gain; 350) and NTA post-acquisition settings were optimized and kept constant
163 between samples. Each video recording was analyzed to infer STB-EVs size and concentration
164 profile.

165 ***Western Blot Analysis***

166 We performed western blots on placental lysates (PL) and STB-EVs to further characterise and
167 immune-phenotype. All STB-EVs pellets were probed with PLAP (for syncytiotrophoblast
168 origin), CD63 and ALIX (to confirm the presence of extracellular vesicles), and Cytochrome C
169 (as a negative EV marker) as recommended by the international society for extracellular vesicles
170 (ISEV) (Théry et al., 2018). Following characterization and identification of extracellular
171 vesicles in 10K and 150K STB-EV pellets, we renamed them to medium/large (m/l) and small
172 (s) STB-EVs respectively.

173 ***RNA-Sequencing Library Preparation and Sequencing***

174 For sequencing, RNA extraction and sample preparations were performed for placenta tissue
175 (discovery cohort-6 NP, 6 PE) with the RNeasy mini kit and STB-EVs (6 NP, 6 PE) with the
176 miRCURY™ RNA isolation kit for biofluids (Exiqon Services, Denmark) based on
177 manufacturer's protocol. The samples were sent to the Wellcome Centre for Human Genetics

178 (WCHG) for sequencing using standard Illumina protocol. Details can be found in the
179 supplementary material.

180 ***Bioinformatics and Statistical Analysis of Messenger RNA sequences***

181 We performed bioinformatics analysis on Galaxy (<https://usegalaxy.org/>). We used FastQC
182 (Galaxy Version 0.72+galaxy1) to obtain overall QC metrics and MultiQC (Galaxy Version
183 1.9+galaxy1) to amalgamate the QC metrics before and after trimming of adapters [trimmomatic
184 (Galaxy Version 0.38.0)]. Alignment was referenced to reference Homo Sapiens build 38 (hg38)
185 genomes obtained from Ensembl with *HISAT 2* (Galaxy Version 2.2.1+galaxy0). For each
186 sample, *featureCounts* (Galaxy Version 2.0.1+galaxy1) was used to quantify genes based on
187 reads that mapped to the provided hg38 genome. A count matrix was generated with the *Column*
188 *Join on Collection* (Galaxy Version 0.0.3) tool. Differential expression analysis was done with
189 the DESeq2 package (v.1.32.0 in R v.4.0.5). The reported p-values were adjusted for multiple
190 testing using Benjamin Hochberg correction reported as false-discovery rate. An adjusted p-
191 value less than 0.05 was taken as significant. Functional annotation was performed with
192 ClusterProfiler (for Gene Ontology [GO] and KEGG) and Signalling pathway impact analysis
193 (SPIA) with our transcriptome set as the background. The raw fastQ files and processed file
194 have been deposited in NCBI and can be accessed with the following ID: GSE190973.

195 ***Criteria for genes selection for validation***

196 We chose a select group of DCGs between NP and PE to validate based on 1) fold change (genes
197 with a high fold change [$\log FC \geq (\pm)1$] and adjusted P Value $\leq 10^{-5}$), 2) presence in at least two
198 of the three sample types (placenta lysate, m/l STB-EVs, and sSTB-EVs), 3) placenta specificity
199 or enrichment and, 4) previous molecules investigated by the group. Based on expression data at

200 the protein and RNA level from the human protein atlas (Uhlen et al., 2017), genes are said to be
201 placenta specific if they are expressed only in the placenta, while genes are placenta enriched if
202 the placenta is one of the five with the highest expression.

203 ***Quantitative polymerase chain reaction (qPCR) for mRNA validation***

204 Following standard protocol, the high-capacity cDNA Reverse transcription kit (Applied
205 Biosystems, USA) was used for reverse transcription of the validation cohort (n =6 [PE], 6
206 [NP]). Quantitative polymerase chain reaction was performed on Quant Studio™ 3 real-time
207 PCR systems, (Quant Studio™ Design and analysis software), MicroAmp™ Optical 96-well
208 reaction plate (N8010560) and optical adhesive film kit (4313663), with the hydrolysis probe-
209 based Taqman (R) gene expression assay (Applied Biosystems, USA). The following settings
210 were used: hold 50°C for 2 minutes, hold at 95°C for 20 seconds, followed by forty 95°C for 1
211 second and 60°C for 20 seconds. Cq values were generated automatically by the Quant Studio
212 Design and Analysis desktop software. The geometric mean of *YWHAZ* and *SDHA* were used as
213 the internal reference genes for the normalization of all qPCR data. We analyzed the qPCR data
214 and calculated fold changes using the $2^{-\Delta\Delta C_t}$ method (Livak & Schmittgen, 2001). Data was
215 expressed as fold change, and standard error is denoted as error bars with GraphPad Prism
216 software (version 9). Statistical testing was made on the ΔC_t values using a one-tailed Student *t*-
217 *test*, and significance was set at $P < 0.05$. All gene expression assays, their corresponding assay
218 IDs, and all other details used in this study are listed in supplementary material.

219

220

221

222

223

224

225 **Results**

226 *Patient demographics and clinical characteristics*

227 There were no significant differences in maternal age, body mass index, and the gender of the
228 neonates (Table 1). The average systolic (178.83 mmHg) and diastolic (109.17 mmHg) blood
229 pressure was significantly higher among the PE cohort ($P < 0.001$). Likewise, there was a
230 significant difference in proteinuria (PE = 2.58; NP = 0 pluses on urine dipstick; $P < 0.001$) and
231 gestational age at delivery (PE = 32.00 weeks gestation, NP = 39.17 weeks gestation $P = 0.001$)
232 in PE compared to NP. Finally, PE neonates were more likely to be growth restricted (100%; 0%
233 $P = 0.004$) with an average birth weight of 1515.83 g compared to 3912.50 g in normal neonates
234 ($P < 0.001$).

235

236

237

238

239

240

241

242

243

244

245 **Table 1.** General characteristics of the transcriptomic cohort study population

Characteristics	Normal Pregnancy	Preeclampsia	P Value
Sample size	6	6	
Maternal age years (mean (SD))	34.50 (5.39)	36.33 (4.13)	0.524
Body mass index kg/m ² (mean (SD))	29.92(9.10)	31.25 (11.12)	0.825
Systolic blood pressure mmHg (mean (SD))	129.50 (4.93)	178.83 (12.56)	<0.001
Diastolic blood pressure mmHg (mean (SD))	67.00 (6.20)	109.17 (9.85)	<0.001
Proteinuria plus(es) (mean (SD))	0	2.58 (1.20)	<0.001
Gestational age at delivery in weeks (mean (SD))	39.17 (0.98)	32.00 (3.52)	0.001
Birth weight (grams) (mean (SD))	3912.50 (730.40)	1515.83 (600.57)	<0.001
Intrauterine growth	0 (0)	6(100)	0.004

restriction (IUGR) = Yes			
(%)⁻			
Male new-born gender (%)	2 (33.3)	2 (33.3)	1.000

246 *Sample size for the transcriptomics cohort (PL [NP=6, PE=6], and STB-EVs [NP=6, PE=6]). q
247 PCR confirmation for PL was performed on the same cohort (PL [NP=6, PE=6]) while STB-EV
248 qPCR validation was performed on a different cohort (NP=6, PE=6)– those patient
249 characteristics in supplementary data.

250

251 ***Characterization of STB-EVs by TEM, NTA, flow cytometry, and WB***

252 We characterized our sample preparations with transmission electron microscopy (TEM),
253 nanotracking analysis (NTA), flow cytometry (FC), and western blot (WB) after the isolation
254 and enrichment of STB-EVs. TEM (Figure 1A) showed the typical cup-shaped morphology of
255 extracellular vesicles. In particular, the 10K STB-EV pellet (Figures 1A2, 1A5 and 1A8) showed
256 a size heterogeneity characteristic of m/ISTB-EVs (221 to 1000 nm) and the 150K STB-EV
257 pellet (Figures 1A3, 1A6, and 1A9) showed a homogeneous EVs size profile (less than or equal
258 to 220 nm). This finding was also replicated by NTA (Figure 1C). The 10K STB-EV (Figure
259 1C1) pellets had a modal size of 479.4 ± 145.6 nm, while the 150K STB-EV (Figure 1C2) pellets
260 had a smaller modal size (205.8 ± 67.7 nm). The post 10K and post 150K pellets are hereafter
261 renamed m/ISTB-EVs and sSTB-EVs, respectively. WB (Figure 1B) detected PLAP (66 KDa),
262 tetraspanins (CD63 [30–65 KDa]), and endosomal trafficking proteins (ALIX [95 KDa]). The
263 non-EV marker cytochrome C (12 KDa) was detected in the placenta lysate but not the STB-EV
264 fractions. Notably, TSG101 and ALIX were more prominent in the sSTB-EV fractions than the
265 m/ISTB-EV fractions and placenta lysate.

266 Flow cytometry (Figure S1) was only performed on the m/ISTB-EVs due to the size detection
267 limit of flow cytometry which does not permit interrogation of small STB-EVs. We found $85 \pm$
268 8.3% (Figure S1C) of qualified events were negative for the following lineage markers (CD41
269 [platelets] and CD235a [red blood cells], and HLA-I and II [white blood cells]). $95 \pm 1.2 \%$ of
270 the EVs negative for non-placental markers (listed above) were BODIPY FL N-(2-aminoethyl)-
271 maleimide (bioM) and placental alkaline phosphatase (PLAP) double-positive (Figure S1D).
272 PLAP is a specific marker of syncytiotrophoblast, and bioM a marker of EVs, so this analysis
273 confirmed that most of the post 10K samples, within the detection size range, were of placental
274 origin. NP-40 (detergent) treatment confirmed that our samples were largely vesicular since only
275 $0.1 \pm 0.12\%$ BODIPY FL N-(2-aminoethyl)-maleimide and PLAP double-positive events were
276 detected (a reduction of 99%) after treatment with detergent (Figure S1E).

277

278

279

280

281

282


283

284

285

286

287



288

289 **Figure 1.** STB-EV characterization. Figure A displays representative transmission electron
290 microscopy (TEM) images with wide view of samples (A1, A4, and A7), medium/large STB-
291 EVs (A2, A5, and A8) displaying heterogeneity of vesicle sizes, and small STB-EVs (A3, A6,
292 and A9) displaying typical cup shaped morphology. Figure 1B is a western blot of placenta
293 homogenate (PL), m/ISTB-EVs (10K) and sSTB-EVs (150K) showing positivity for PLAP in all
294 samples confirming placental origin. sSTB-EVs express enhanced levels of ALIX and CD63
295 which are known exosomal markers. The absence of cytochrome C in the STB-EV population

296 confirms no contamination. Figure 1C shows the NTA results of m/l STB-EVs (C1) which show
297 a broad size distribution and sSTB-EVs (C2) which display a more homogeneous size.

298

299 *Differentially carried genes (DCGs) in placenta homogenate, m/lSTB-EVs and sSTB-EVs*
300 *between PE and NP*

301 Transcriptomic analysis was performed on the discovery cohort (n=6 [PE], 6 [NP]). Comparison
302 between PE and NP placental tissue revealed 580 upregulated and 563 downregulated (total)
303 genes (adjusted P value of $< 10^{-5}$ [Figures S3]) while in m/lSTB-EVs 1,128 were upregulated
304 and 833 were downregulated (adjusted P value of $< 10^{-5}$ [Figures 2]). In sSTB-EVs, 232 were
305 upregulated, and 106 were downregulated (adjusted P value of $< 10^{-5}$ [Figures S4]). We noted
306 25 downregulated genes, and 120 upregulated genes were common to all three sample types.

307

308

309

310

311

312

313

314

315


327

328

329 ***Quantitative PCR (qPCR) Validation of selected Genes***


330 Quantitative PCR was performed on a different subset of STB-EVs, the validation cohort (n=6
331 [PE], 6 [NP]). As earlier discussed in the methods section, we identified the DCGs that were
332 common between all three sample types (common DCGs) and of those, we selected a subset that
333 were placenta enriched or specific based the criteria mentioned in the methods section. We
334 selected *HTRA4*, *PAPP-A2*, *EBI3*, *HSD17B1*, *FSTL3*, *INHBA*, *SIGLEC6*, and *CGB3*. We
335 performed qPCR analysis of these genes in both m/STB-EVs and sSTB-EVs. As a proof of
336 concept, four of these genes known to be altered in PE in placental tissues (*LEP*, *COL17A1*,
337 *SLC45A4*, and *FLNB*) were analyzed in the placenta and we confirmed that these genes were
338 indeed significantly altered in PE (Figure 3). We next moved on to the species of interest and
339 showed that in the m/l STB-EVs (Figures 3 and 4), *LEP*, *SIGLEC6*, *FLNB*, *COL17A1*, *SLC45A4*,
340 *FSTL3*, and *HTRA4* were significantly different in PE compared to NP.

341 In sSTB-EVs, (Figure 3 and 4) all the selected genes (except for *SLC45A4* and *HSD17B1*) were
342 significantly different. Across the three sample types, *LEP*, *COL17A1*, and *FLNB* were all
343 significantly different between PE and NP while *SIGLEC6*, *FSTL3*, and *HTRA4* were
344 significantly different in both m/l and sSTB-EVs.



345

346 **Figure 3.** Quantitative PCR validation of selected differentially expressed/carried genes leptin
347 (LEP), collagen type XVII alpha 1 chain (COL17A1), solute carrier family 45 member 4
348 (SLC45A4), filamin B (FLNB) and endoglin (ENG) in the placenta, medium/large STB-EVs and
349 small STB-EVs. Data is visualized as mean fold change and error bars represent standard error.
350 *=P <0.05, **=P <0.01, ***=P <0.001, and ****=P <0.0001. Sample size (n) = 6(NP) and 6(PE)
351



352

353 **Figure 4.** Quantitative PCR validation of placenta specific genes; pappalysin 2 (PAPP-A2),
 354 inhibin subunit beta A (INHBA), sialic acid binding Ig like lectin 6 (SIGLEC6), HtrA serine
 355 peptidase 4 (HTRA4), Epstein-Barr virus-induced 3 (EBI3), follistatin like 3 (FSTL3),
 356 hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1), chorionic gonadotropin 3 (CGB3) and
 357 age-related macular degeneration (ARMS2) in medium/large STB-EVs and small STB-EVs
 358 based on qPCR. Data is visualized as mean fold change, and error bars represent standard error.
 359 *=P <0.05, **=P <0.01, ***=P <0.001, and ****=P <0.0001. Sample size (n) = 4(NP) and
 360 4(PE).

361

362

363

364

365 *Functional enrichment analysis and Signalling pathway impact analysis (SPIA) of*
366 *differentially expressed genes (DEGs) in preeclampsia (PE)*

367 To understand the role of these genes and perhaps STB-EVs in the pathophysiology of
368 preeclampsia, we performed a functional enrichment analysis (with overrepresentation analysis)
369 on the list of DCGs (between NP and PE) for placenta tissue, m/ISTB-EVs, and sSTB-EVs and
370 identified functional processes that overlap among the three sample subtypes. There were 32
371 similar biological processes between the placenta and sSTB-EVs (See full list Table S4). One
372 biological process was similar between the placenta and m/ISTB-EVs (*platelet degranulation*),
373 two biological processes; *cell adhesion molecule* and *integrin-binding* common to both placenta
374 and sSTB-EVs and no biological process was common to all sample subtypes.

375 When analysing KEGG pathways, *focal adhesion* was overrepresented among all three sample
376 types while the *HIF-1 signalling pathway*, *proteoglycans in cancer*, *central carbon metabolism*
377 *in cancer* were overrepresented in both placental tissue and sSTB-EVs.

378 Signalling pathway impact analysis of the DEGs in placental tissue homogenate showed
379 *neuroactive ligand-receptor interaction*, *ECM-receptor interaction*, *focal adhesion*, *amoebiasis*,
380 and *gap junction* as the most overrepresented. Of these five, all were inhibited except the
381 *neuroactive ligand-receptor interaction*, which was activated. In contrast, the same analysis on
382 m/ISTB-EVs revealed two significantly dysregulated pathways, *focal adhesion*, and *cytokine-*
383 *cytokine interaction pathways*, both of which were activated. Similarly, in sSTB-EVs, three
384 pathways *adipocytokine*, *focal adhesion*, and *type II DM* were significantly activated. Among all
385 three sample types, *focal adhesion* was common to all.

386

387 **Discussion**

388 **Principal findings**

389 In recent years, extracellular vesicles (EVs) have gained interest, particularly their role in the
390 context of PE, their potential to affect functional changes in organs distant from the placenta, and
391 their ability to act as circulating liquid biopsies, revealing data about the donor cells in real-time.
392 Our analysis found the STB-EV transcriptomic signature in PE to be different than in NP. We
393 identified and validated STB-EV mRNAs—*FLNB*, *COL17A1*, *SLC45A4*, *LEP*, *HTRA4*,
394 *PAPP-A2*, *EBI3*, *HSD17B1*, *FSTL3*, *INHBA*, *SIGLEC6*, and *CGB3*. Exploration of these
395 differentially abundant mRNAs as circulating biomarkers may help early identification of PE.

396 **Results in the context of what is known.**

397 Some of the findings of this study such as *FLT1*, *LEP* (Tsai et al., 2011b), *ENG*, *PAPP-A2* (Guo
398 et al., 2021), *FSTL3*, *PRG2* (Gormley et al., 2017), *INHBA* (Brew et al., 2016), have been well
399 described in the placenta but not previously described in STB-EVs. These STB-EV associated
400 mRNA may account for some circulating mRNA such as *PAPP-A2*, *LEP*, and *HTRA4* (Munchel
401 et al., 2020) detected in increased amounts in PE patients. We opted to validate the following
402 genes: *FLNB*, *COL17A1*, *SLC45A4*, *LEP*, *ENG*, *HTRA4*, *PAPP-A2*, *EBI3*, *HSD17B1*, *ARMS2*,
403 *FSTL3*, *INHBA*, *SIGLEC6*, and *CGB3* since these fulfilled the criteria for biomarkers as outlined.
404 We discovered that on m/STB-EVs, *FLNB*, *COL17A1*, *SLC45A4*, *LEP*, *FSTL3*, *HTRA4* and
405 *SIGLEC6* were significantly differentially expressed between PE and normal. Equally
406 interestingly, in sSTB-EVs we found that except for *HSD17B1*, all the other genes were
407 differentially carried between PE and normal.

408 LEP was the most significantly elevated gene in placental tissue, m/ISTB-EV and sSTB-EVs.
409 The discovery of LEP in STB-EVs is novel. The role of its protein, not its mRNA, as a potential
410 biomarker has been suggested previously(Taylor et al., 2015). LEP plays a role in endocrine
411 functions, reproduction, immune function and is produced by the placenta, aiding implantation,
412 and regulating placental growth (Castellucci et al., 2000). The dysregulation of leptin has been
413 linked to pregnancy complications with higher circulating protein levels associated with PE
414 (Masuyama et al., 2010).

415 Similarly, we found significantly elevated COL17A1 in the placenta, m/ISTB-EV and sSTB-EV.
416 COL17A1 is a collagen transmembrane protein involved in extracellular matrix receptor
417 interactions. It has been identified, through mass spectrometry, to be differentially expressed in
418 urine samples from PE. In contrast, we found that SLC45A4 mRNA was significantly
419 downregulated in both types of vesicles. *SLC45A4* protein is involved in promoting glycolysis
420 and autophagy prevention (Chen et al., 2021), two processes found to be abnormal in PE
421 (Bloxam et al., 1987).

422 *FLNB* is an essential cytoskeletal protein critical in endothelial cell motility and that has been
423 previously reported to be downregulated in PE placentae at the mRNA and protein level(Tejera
424 et al., 2013; Wei et al., 2019). This contrasts with our study which showed that *FLNB* gene was
425 significantly elevated in placenta and in m/ISTB-EV and sSTB-EV. It is difficult to identify the
426 exact reason for the variance, but the choice of housekeeping gene may be a possible
427 explanation. Wei et al used β *actin* which has been observed to be variable and a potential
428 confounder in other disease states or experimental conditions (Glare et al., 2002) . We used the
429 geometric mean of *YWHAZ* and *SDHA*; both previously shown to be stably expressed(Meller et
430 al., 2005)

431 Our analysis also showed that SIGLEC6 was differentially present in both subset of STB-EVs.
432 Our group had previously reported the presence in higher concentration in PE placentas
433 compared to NP(Awoyemi et al., 2020). *SIGLEC6* regulates immune cell by interacting with
434 sialic acid on these cells and inhibiting cellular activation and clonal expansion (Zhang et al.,
435 2007) through cytosolic tyrosine-based regulatory motif (Brinkman-Van der Linden et al., 2007).
436 *FSTL3* glycoprotein is localized to the decidua and has been well documented to be present in
437 abundance in PE placenta and plasma samples. (Xie et al., 2018) (Founds et al., 2015). Our
438 analysis demonstrates that this elevation is also mirrored at the mRNA level in STB-EVs.
439 *HTRA4* was found to be differentially carried in PE STB-EVs in our analysis. HTRA4 is a
440 placental-specific serine protease that inhibits cell cycle progression and cell differentiation to
441 endothelial cells (Wang et al., 2019). *HTRA4* may be responsible for endothelial cell
442 dysregulation by disrupting endothelial tube formation and increasing endothelial cell
443 permeability (Singh et al., 2015).

444 We also attempted to provide mechanistic insights into the roles of these differentially carried
445 genes in the pathogenesis of PE. We identified *HIF 1 pathway, blood vessel development* (Guo
446 et al., 2021), *adipocyte regulation, retinoic acid regulation, hypoxic signaling, associated*
447 *cytokine pathways* (Benny et al., 2020), *PI3/Akt signaling, and pathways in cancer* (Li & Fang,
448 2019) as pathways that are potentially contributory. We also found several less well characterized
449 and potentially relevant pathways such as *processes involved with protein catabolism and*
450 *degradation, insulin and other growth factor receptor signaling pathways, nervous system*
451 *development, ion channel activities, transcription repression*, among others. Interestingly, the
452 signalling pathway impact analysis found that the *focal adhesion pathway* was inhibited in the
453 placenta but activated in both STB-EV subtypes. *Cytokine-cytokine interactions* were activated

454 in m/STB-EVs, while *type II DM* (diabetes mellitus) and *adipocytokine* pathways were activated
455 in sSTB-EVs. The risk of PE is known to be increased by 2-4-fold among type II DM patients,
456 and women with a history of PE are more likely to develop type II DM later in life(Weissgerber &
457 Mudd, 2015). None of the patients used in this study had been diagnosed with diabetes mellitus. If
458 they had, it may have explained why this pathway was activated in our analysis. It may be
459 interesting to explore, in the future, if sSTB-EVs play a role in this association or if this
460 association is due to the presence of comorbid conditions common to both PE and DM.

461 Finally, *focal adhesion* is a critical step in cell and extracellular matrix (ECM) interaction and
462 perhaps interactions between the trophoblast and the ECM and is crucial in trophoblastic
463 invasion and PE (He et al., 2015). In our analysis, we found this pathway to be inhibited in the
464 placenta but activated in m/l and sSTB-EVs. It is reasonable to assume that the differences in the
465 GO terms and pathways among all sample types may portray a difference in roles between the
466 placenta, M/L STB-EVs, and S STB-EVs in the pathogenesis of the disease. However, we
467 believe these differences may be best explored in future studies.

468 **Ideas and Speculations**

469 Our findings have identified several potential STB-EV mRNA biomarkers which require
470 external validation especially in biofluids like plasma, serum, or urine. The prospect of a qPCR
471 biomarker panel is interesting as a qPCR panel should be cheaper and easier to implement than a
472 quantitative protein assay. Such tests are easily scalable and if validated might even be adaptable
473 to low-income resource settings using Loop-Mediated Isothermal Amplification (LAMP) PCR, a
474 PCR technique that can be performed at room temperature. Since transcriptome level alterations
475 precedes proteome level alterations, mRNA based biomarkers may theoretically be better at

476 ascertaining the risk of developing preeclampsia before the development of clinical symptoms
477 than standard of care.

478 **Strengths and limitations**

479 Our study is not without limitations that should be considered while interpreting the results. First,
480 our sample size is relatively small and thus no predictive analysis could be conducted. Secondly,
481 it is difficult to find a gestational age matched control for PE, particularly the early onset
482 phenotype (< 34 weeks). Therefore, we used term (37 to 41⁺⁶ weeks) controls. This is a standard
483 approach for all scientists working on PE placentas. Lastly, like most studies on PE, the samples
484 are from deliveries. It is possible these biomarkers represent differences observed at end-stage
485 disease and would require further research to translate these markers to early developmental
486 stages. Notwithstanding, this study has numerous positives, particularly our ability to utilize a
487 comprehensive analysis of three linked sample types from the same patient. This has permitted
488 the dissection of differences between the tissue and the EVs and identification of some
489 potentially exciting pathways which may form the basis of further research.

490 **Conclusions**

491 Despite intensive efforts, the pathophysiology of preeclampsia (PE) has still not been completely
492 unraveled. In this study, we identified potential mRNA biomarkers and mechanistic gene
493 pathways that may be important in the pathophysiology of PE and could be further explored in
494 future studies. The potential utilization of STB-EVs based mRNA as circulating biomarkers with
495 real time placental and fetal information may be important in early PE diagnosis and mechanism.

496 **Acknowledgments**

497 We acknowledge the support of the National Institute of Health Research Clinical Research

498 Network Fenella Roseman & Lotoyah Carty research for assistance in patient recruitment.

499

500 **Competing interests:**

501 The authors declare no competing interests.

502 **References**

503 Awoyemi, T., Tannetta, D., Zhang, W., Kandzija, N., Motta-Mejia, C., Fischer, R., Heilig, R., Raiss, S.,
504 Redman, C., & Vatish, M. (2020). Glycosylated Siglec-6 expression in syncytiotrophoblast-derived
505 extracellular vesicles from preeclampsia placentas. *Biochemical and Biophysical Research*
506 *Communications*, 533(4), 838–844. <https://doi.org/10.1016/j.bbrc.2020.09.081>

507 Benny, P. A., Alakwaa, F. M., Schlueter, R. J., Lassiter, C. B., & Garmire, L. X. (2020). A review of omics
508 approaches to study preeclampsia. *Placenta*, 92, 17–27.
509 <https://doi.org/10.1016/j.placenta.2020.01.008>

510 Bloxam, D. L., Bullen, B. E., Walters, B. N. J., & Lao, T. T. (1987). Placental glycolysis and energy
511 metabolism in preeclampsia. *American Journal of Obstetrics and Gynecology*, 157(1), 97.
512 [https://doi.org/10.1016/S0002-9378\(87\)80354-X](https://doi.org/10.1016/S0002-9378(87)80354-X)

513 Brew, O., Sullivan, M. H. F., & Woodman, A. (2016). Comparison of normal and pre-eclamptic placental
514 gene expression: A systematic review with meta-analysis. *PLoS ONE*, 11(8), 1–20.
515 <https://doi.org/10.1371/journal.pone.0161504>

516 Brinkman-Van der Linden, E. C., Hurtado-Ziola, N., Hayakawa, T., Wiggleton, L., Benirschke, K., Varki, A.,
517 & Varki, N. (2007). Human-specific expression of Siglec-6 in the placenta. *Glycobiology*, 17(9), 922–
518 931. <https://doi.org/10.1093/glycob/cwm065>

519 Brown, M. A., Magee, L. A., Kenny, L. C., Karumanchi, S. A., McCarthy, F. P., Saito, S., Hall, D. R., Warren,
520 C. E., Adoyi, G., & Ishaku, S. (2018). Hypertensive disorders of pregnancy: ISSHP classification,
521 diagnosis, and management recommendations for international practice. *Hypertension*, 72(1), 24–
522 43. <https://doi.org/10.1161/HYPERTENSIONAHA.117.10803>

523 Castellucci, M., De Matteis, R., Meisser, A., Canello, R., Monsurrò, V., Islami, D., Sarzani, R., Marzioni,
524 D., Cinti, S., & Bischof, P. (2000). Leptin modulates extracellular matrix molecules and
525 metalloproteinases: Possible implications for trophoblast invasion. *Molecular Human*
526 *Reproduction*, 6(10), 951–958. <https://doi.org/10.1093/molehr/6.10.951>

527 Chen, W., Huang, F., Huang, J., Li, Y., Peng, J., Zhuang, Y., Huang, X., Lu, L., Zhu, Z., & Zhang, S. (2021).
528 SLC45A4 promotes glycolysis and prevents AMPK/ULK1-induced autophagy in TP53 mutant

- 529 pancreatic ductal adenocarcinoma. *Journal of Gene Medicine*, 23(9), 1–12.
530 <https://doi.org/10.1002/jgm.3364>
- 531 Colombo, M., Raposo, G., & Théry, C. (2014). Biogenesis, secretion, and intercellular interactions of
532 exosomes and other extracellular vesicles. *Annual Review of Cell and Developmental Biology*, 30,
533 255–289. <https://doi.org/10.1146/annurev-cellbio-101512-122326>
- 534 Dragovic, R. A., Collett, G. P., Hole, P., Ferguson, D. J. P., Redman, C. W., Sargent, I. L., & Tannetta, D. S.
535 (2015). Isolation of syncytiotrophoblast microvesicles and exosomes and their characterisation by
536 multicolour flow cytometry and fluorescence Nanoparticle Tracking Analysis. *Methods*, 87, 64–74.
537 <https://doi.org/10.1016/j.ymeth.2015.03.028>
- 538 Founds, S. A., Ren, D., Roberts, J. M., Jeyabalan, A., & Powers, R. W. (2015). Follistatin-like 3 across
539 gestation in preeclampsia and uncomplicated pregnancies among lean and obese women.
540 *Reproductive Sciences*, 22(4). <https://doi.org/10.1177/1933719114529372>
- 541 Glare, E. M., Divjak, M., Bailey, M. J., & Walters, E. H. (2002). β -actin and GAPDH housekeeping gene
542 expression in asthmatic airways is variable and not suitable for normalising mRNA levels. *Thorax* 77,
543 57(9), 765–770. <https://doi.org/10.1136/thorax.57.9.765>
- 544 Gormley, M., Ona, K., Kapidzic, M., Garrido-Gomez, T., Zdravkovic, T., & Fisher, S. J. (2017).
545 Preeclampsia: novel insights from global RNA profiling of trophoblast subpopulations. *American*
546 *Journal of Obstetrics and Gynecology*, 217(2), 1–17. <https://doi.org/10.1016/j.ajog.2017.03.017>
- 547 Guo, F., Zhang, B., Yang, H., Fu, Y., Wang, Y., Huang, J., Cheng, M., Li, X., Shen, Z., Li, L., He, P., Xiang, A.
548 P., Wang, S., & Zhang, H. (2021). Systemic transcriptome comparison between early- And late-
549 onset pre-eclampsia shows distinct pathology and novel biomarkers. *Cell Proliferation*, 54(2), 1–15.
550 <https://doi.org/10.1111/cpr.12968>
- 551 He, P., Shao, D., Ye, M., & Zhang, G. (2015). Analysis of gene expression identifies candidate markers and
552 pathways in pre-eclampsia. *Journal of Obstetrics and Gynaecology*, 35(6), 578–584.
553 <https://doi.org/10.3109/01443615.2014.990430>
- 554 Li, X., & Fang, Y. (2019). Bioinformatics identification of potential genes and pathways in preeclampsia
555 based on functional gene set enrichment analyses. *Experimental and Therapeutic Medicine*, 18(3),
556 1837–1844. <https://doi.org/10.3892/etm.2019.7749>
- 557 Lisonkova, S., & Joseph, K. S. (2013). Incidence of preeclampsia: risk factors and outcomes associated
558 with early- versus late-onset disease. *Am J Obstet Gynecol*, 209(6), 544 e1-544 e12.
559 <https://doi.org/10.1016/j.ajog.2013.08.019>
- 560 Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time
561 quantitative PCR and the $2^{-\Delta\Delta CT}$ method. *Methods*, 25(4), 402–408.
562 <https://doi.org/10.1006/meth.2001.1262>
- 563 Masuyama, H., Segawa, T., Sumida, Y., Masumoto, A., Inoue, S., Akahori, Y., & Hiramatsu, Y. (2010).
564 Different profiles of circulating angiogenic factors and adipocytokines between early- and late-
565 onset pre-eclampsia. *BJOG: An International Journal of Obstetrics and Gynaecology*, 117(3), 314–
566 320. <https://doi.org/10.1111/j.1471-0528.2009.02453.x>

- 567 Meller, M., Vadachkoira, S., Luthy, D. A., & Williams, M. A. (2005). Evaluation of housekeeping genes in
568 placental comparative expression studies. *Placenta*, *26*(8–9), 601–607.
569 <https://doi.org/10.1016/J.PLACENTA.2004.09.009>
- 570 Munchel, S., Rohrback, S., Randise-Hinchliff, C., Kinnings, S., Deshmukh, S., Alla, N., Tan, C., Kia, A.,
571 Greene, G., Leety, L., Rhoa, M., Yeats, S., Saul, M., Chou, J., Bianco, K., O’Shea, K., Bujold, E.,
572 Norwitz, E., Wapner, R., ... Kaper, F. (2020). Circulating transcripts in maternal blood reflect a
573 molecular signature of early-onset preeclampsia. *Science Translational Medicine*, *12*(550).
574 <https://doi.org/10.1126/SCITRANSLMED.AAZ0131>
- 575 Redman, C. (2014). Pre-eclampsia: A complex and variable disease. *Pregnancy Hypertens*, *4*(3), 241–242.
576 <https://doi.org/10.1016/j.preghy.2014.04.009>
- 577 Redman, C. W. G., Staff, A. C., & Roberts, J. M. (2022). Syncytiotrophoblast stress in preeclampsia: the
578 convergence point for multiple pathways. *American Journal of Obstetrics and Gynecology*, *226*(2S),
579 S907–S927. <https://doi.org/10.1016/J.AJOG.2020.09.047>
- 580 Ren, Z., Gao, Y., Gao, Y., Liang, G., Chen, Q., Jiang, S., Yang, X., Fan, C., Wang, H., Wang, J., Shi, Y. W.,
581 Xiao, C., Zhong, M., & Yang, X. (2021). Distinct placental molecular processes associated with early-
582 onset and late-onset preeclampsia. *Theranostics*, *11*(10), 5028–5044.
583 <https://doi.org/10.7150/thno.56141>
- 584 Rumer, K. K., Uyenishi, J., Hoffman, M. C., Fisher, B. M., & Winn, V. D. (2013). Siglec-6 expression is
585 increased in placentas from pregnancies complicated by preterm preeclampsia. *Reproductive*
586 *Sciences*. <https://doi.org/10.1177/1933719112461185>
- 587 Singh, H., Zhao, M., Chen, Q., Wang, Y., Li, Y., Kaitu’U-Lino, T. J., Tong, S., & Nie, G. (2015). Human HtrA4
588 expression is restricted to the placenta, is significantly Up-regulated in early-onset preeclampsia,
589 and high levels of HtrA4 cause endothelial dysfunction. *Journal of Clinical Endocrinology and*
590 *Metabolism*, *33*(4), 5058–5066. <https://doi.org/10.1210/jc.2014-3969>
- 591 Taylor, B. D., Ness, R. B., Olsen, J., Hougaard, D. M., Skogstrand, K., Roberts, J. M., & Haggerty, C. L.
592 (2015). Serum leptin measured in early pregnancy is higher in women with preeclampsia compared
593 with normotensive pregnant women. *Hypertension*, *65*(3), 594–599.
594 <https://doi.org/10.1161/HYPERTENSIONAHA.114.03979>
- 595 Tejera, E., Bernardes, J., & Rebelo, I. (2013). Co-expression network analysis and genetic algorithms for
596 gene prioritization in preeclampsia. *BMC Medical Genomics*, *6*(51), 1–10.
597 <https://doi.org/10.1186/1755-8794-6-51>
- 598 Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A.,
599 Arab, T., Archer, F., Atkin-Smith, G. K., Ayre, D. C., Bach, J. M., Bachurski, D., Baharvand, H., Balaj,
600 L., Baldacchino, S., Bauer, N. N., Baxter, A. A., Bebawy, M., ... Zuba-Surma, E. K. (2018). Minimal
601 information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the
602 International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *Journal of*
603 *Extracellular Vesicles*, *7*(1), 1–43. <https://doi.org/10.1080/20013078.2018.1535750>
- 604 Tsai, S., Hardison, N. E., James, A. H., Motsinger-Reif, A. A., Bischoff, S. R., Thames, B. H., & Piedrahita, J.
605 A. (2011a). Transcriptional profiling of human placentas from pregnancies complicated by

- 606 preeclampsia reveals dysregulation of sialic acid acetyltransferase and immune signaling pathways.
607 *Placenta*, 32(2), 175–182. <https://doi.org/10.1016/j.placenta.2010.11.014>
- 608 Tsai, S., Hardison, N. E., James, A. H., Motsinger-Reif, A. A., Bischoff, S. R., Thames, B. H., & Piedrahita, J.
609 A. (2011b). Transcriptional profiling of human placentas from pregnancies complicated by
610 preeclampsia reveals dysregulation of sialic acid acetyltransferase and immune signaling pathways.
611 *Placenta*, 32(2), 175–182. <https://doi.org/10.1016/j.placenta.2010.11.014>
- 612 Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors,
613 F., Sanli, K., Von Feilitzen, K., Oksvold, P., Lundberg, E., Hober, S., Nilsson, P., Mattsson, J., Schwenk,
614 J. M., Brunnström, H., ... Ponten, F. (2017). A pathology atlas of the human cancer transcriptome.
615 *Science*, 357(6352). <https://doi.org/10.1126/science.aan2507>
- 616 Wang, Y., Lim, R., & Nie, G. (2019). HtrA4 may play a major role in inhibiting endothelial repair in
617 pregnancy complication preeclampsia. *Scientific Reports*, 9(1), 1–14.
618 <https://doi.org/10.1038/s41598-019-39565-9>
- 619 Wei, J., Fu, Y., Mao, X., Jing, Y., Guo, J., & Ye, Y. (2019). Decreased Filamin b expression regulates
620 trophoblastic cells invasion through ERK/MMP-9 pathway in pre-eclampsia. *Ginekologia Polska*,
621 90(1), 39–45. <https://doi.org/10.5603/GP.2019.0006>
- 622 Weissgerber, T. L., & Mudd, L. M. (2015). Preeclampsia and Diabetes. In *Current Diabetes Reports* (Vol.
623 15, Issue 3). <https://doi.org/10.1007/s11892-015-0579-4>
- 624 Xie, J., Xu, Y., Wan, L., Wang, P., Wang, M., & Dong, M. (2018). Involvement of follistatin-like 3 in
625 preeclampsia. *Biochemical and Biophysical Research Communications*, 506(3):692–697(3), 692–697.
626 <https://doi.org/10.1016/j.bbrc.2018.10.139>
- 627 Yáñez-Mó, M., Siljander, P. R. M., Andreu, Z., Zavec, A. B., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E.,
628 Cappello, F., Carvalho, J., Colás, E., Cordeiro-Da Silva, A., Fais, S., Falcon-Perez, J. M., Ghobrial, I. M.,
629 Giebel, B., Gimona, M., Graner, M., Gursel, I., ... De Wever, O. (2015). Biological properties of
630 extracellular vesicles and their physiological functions. *Journal of Extracellular Vesicles*, 4(1), 1–60.
631 <https://doi.org/10.3402/jev.v4.27066>
- 632 Zhang, M., Angata, T., Cho, J. Y., Miller, M., Broide, D. H., & Varki, A. (2007). Defining the in vivo function
633 of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. *Blood*, 109(10), 4280–4287.
634 <https://doi.org/10.1182/blood-2006-08-039255>
- 635
- 636
- 637
- 638

639

640

641 **Supplementary Material**

642 Supplemental Methods

643 Table S1-S4

644 Figure S1-S4

645 List of differentially abundant mRNA and functional enrichment analysis:

646 DOI: [10.17632/6s5fkd3z7t.1](https://doi.org/10.17632/6s5fkd3z7t.1)

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

Supplemental Material

668

669

670

671

672

673

674

675

676

677 **Supplemental Methods**

678 ***Enrichment of STB-EVs by placental dual-lobe perfusion and serial ultracentrifugation***

679 Briefly, we identified a suitable cotyledon (devoid of calcifications, ischemia, or rupture) and
680 cannulated a placental artery and vein perfusing the placenta for three hours at a 4-5 ml/min flow
681 rate to obtain placenta perfusate. The placenta perfusate was centrifuged twice at 1,500 g for ten
682 minutes at 4°C (*Beckman Coulter Avanti J-20XP centrifuge using a Beckman Coulter JS-5.3*
683 *swing-out rotor*) to remove cell debris. The supernatant was carefully pooled and spun at 10,000
684 g (10K) in a swing bucket centrifuge (*Beckman L80 ultracentrifuge and Sorvall TST28.39 swing-*
685 *out rotor*) at 4°C for 30 minutes. The 10K STB-EV pellet was washed with filtered phosphate
686 buffer saline (fPBS) followed by resuspension of the 10K STB-EV pellets in fPBS. An aliquot of
687 the resuspended pellets was analysed to identify and characterise STB-EVs, while the rest were
688 aliquoted to obtain a protein concentration around 2-5 µg/µl (measured using a Pierce
689 bicinchoninic acid (BCA) protein assay) and immediately stored at -80°C. The post-10K
690 supernatant was filtered through a 0.22 µm Millipore stericup filtration device, then spun at
691 150,000 g for 2 hours (*Beckman L80 ultracentrifuge with a Sorvall TST28.39 swing-out rotor*)
692 and the 150K STB-EV pellets were washed, resuspended in fPBS and aliquoted like the 10K
693 STB-EV pellets. This working stock was used for subsequent analysis.

694 ***Transmission electron microscopy***

695 STB-EV pellets were diluted with fPBS to achieve an STB-EV solution with concentrations
696 between 0.1-0.3 µg/µl. Ten microliter of the STB-EV pellet solution was applied to freshly

697 glowing discharged carbon formvar 300 mesh copper grids for two minutes, blotted with filter
698 paper, and stained with 2% uranyl acetate for ten seconds and air-dried. STB-EV pellets on the
699 grid were negatively stained to enhance the contrast between STB-EVs pellets and the
700 background. The grids were imaged using an FEI Tecnai 12 TEM at 120 kV with a Gatan
701 OneView CMOS camera.

702 *Flow Cytometry*

703 A BD LSRII flow cytometer (BD Biosciences) with a blue, violet, and red laser was used for all
704 sample analyses. Daily quality control (QC) was run using CS&T beads (BD Biosciences).
705 Photomultiplier tube (PMT) voltage determined by CS&T run was applied to all fluorescent
706 detectors with exception for the side scatter (SSC) which was determined by Apogee Mix (1493,
707 Apogee Flow System, UK). SSC PMT voltage that triggered 0.59 μm silica beads and above was
708 applied to all 10K STB-EV pellets and analyzed. An SSC threshold of 200 was applied to
709 remove background noise below 0.59 μm silica beads. A flow rate of 10 $\mu\text{l}/\text{min}$ was achieved
710 using the TruCount beads (BD science). For sample staining, 90 ml of 10K STB-EV pellet were
711 incubated with ten ml of Fc receptor blocker (Miltenyl, UK) for 10 minutes at 4^oC and then
712 stained with phycoerythrin (PE) conjugated PLAP (for syncytiotrophoblast origin), PE Vio770
713 conjugated anti classical HLA class I and II (to exclude co-isolated non-placenta EVs and white
714 blood cell (WBC) EV co-isolation), Pacific blue conjugated CD41 (to identify co-isolated
715 platelet EVs) and CD235a (to identify co-isolated red blood cell (RBC) EVs) for ten minutes at
716 room temperature in the dark. Stained samples were transferred to an Ultra free 0.2 μm filter unit
717 (Millipore) and centrifuged at 800 g for three minutes to remove unbound antibodies and EVs
718 smaller than the filter pore size. Ninety microliters of fPBS were used to recover 10K STB-EVs
719 retained on the filter membrane. Recovered 10K STB-EVs were further stained with BODIPY

720 FL N-(2-aminoethyl)-maleimide [505/513 nm] (Molecular Probes) at a final concentration of 0.5
721 nM in the dark at room temperature for ten minutes before samples were diluted to 500 ml and
722 analyzed on the flow cytometer to check for events rate. When necessary, dilutions were made to
723 achieve an events rate of ≤ 400 count/second and to reduce swarming. 10K STB-EV pellets were
724 analyzed at 10 μ l/minute for ten minutes and a total of 100 μ l diluted samples was analyzed for
725 each sample. Fluorescence minus one (FMO-1) for each fluorochrome and stained samples re-
726 acquired after 2% Nonidet P-40 (NP-40) (Sigma) treatment were used as controls. Data and
727 figures generated were generated with the Flowjo software version 10 (Tree Star Inc., Ashland,
728 OR).

729

730

731

732

733

734

735

736

737


738

739

740

741

742 Flow Cytometry




743

744 **Figure S1.** Representative flow analysis of m/ISTB-EVs enriched by placental
745 perfusion. Apogee beads mix was used to set the flow machine's light scatter resolution to 0.59-
746 1.3 mm silica beads (Figure S1A); Application of SSC and FSC PMTVs determined by apogee
747 beads mix for the analysis of M/L STB-EVs (Figure S1B). An investigation gate interrogating
748 m/l STB- EVs which did not express the non-placental markers HLA Class 1 & II, CD41a and
749 CD235a – thus removing co-isolated non-placental EVs (Figure S1C). STB-EVs from the
750 investigation gate were further analyzed for expression of PLAP and staining by bioM- which

751 stains proteins (Figure S1D). This revealed a high number (95%) of PLAP positive vesicles.
752 These PLAP+ bioM+ double positive EVs were highly sensitive to detergent treatment (Panel E)
753 with the reduction in PLAP+ bioM+ double positivity confirming that they are vesicular in
754 nature.

755



756

757 **Figure S2.** Reagent controls, 0.1mm filtered PBS (A); 0.2mm filtered bioM (B) and antibody
758 cocktail (C) all showing no PLAP+ bioM+ double positivity. Fluorescent minus one (FMO-1)
759 controls, bioM-1 control (D); PE Vio770-1 control (E); PE-1 control (F).

760

761

762

763

764 ***Nanoparticle Tracking Analysis***

765 We further characterised the 10K and 150K STB-EV pellets by nanoparticle tracking analysis
766 [(NTA) NanoSight NS500 instrument equipped with a 405 nm laser (Malvern UK), sCMOS
767 camera and NTA software version 2.3, Build 0033 (Malvern UK)]. Before sample analysis,
768 instrument performance was checked with silica 100 nm microspheres (Polysciences, Inc.). The
769 10K and 150K STB-EV pellets were individually diluted in fPBS to a range of 1/100,000. The
770 samples were automatically injected into the sample chamber with a 1 ml syringe with the
771 following script used for EV measurements: prime, delay 5, capture 60, repeat 4. Images of the
772 analyzed samples were captured on camera at level 12 (Camera shutter speed; 15 milliseconds
773 and Camera gain; 350) and NTA post-acquisition settings were optimized and kept constant
774 between samples. Each video recording was analyzed to infer STB-EVs size and concentration
775 profile.

776 ***Western Blot Analysis***

777 We performed western blots on placental lysates (PL) and STB-EVs to further characterise and
778 immune-phenotype. All STB-EVs pellets were probed with PLAP (for syncytiotrophoblast
779 origin), CD63 and ALIX (to confirm the presence of extracellular vesicles), and Cytochrome C
780 (as a negative EV marker) as recommended by the international society for extracellular vesicles
781 (ISEV) (Théry et al., 2018). Following characterization and identification of extracellular
782 vesicles in 10K and 150K STB-EV pellets, we renamed them to medium/large (m/l) and small
783 (s) STB-EVs respectively.

784

785

786

787 **Table S1.** Table showing the antibodies used for Western blot.

Antibodies	Concentration	Dilution	Antigen	Specificity	Manufacturer
Anti-PLAP (NDOG 2)	1.6 µg/µl	1/1000	PLAP	STB-EV	In house antibody
Anti-CD63	200 µg/µl	1/1000	CD63	STB-EV	Santa Cruz Biotechnology
Anti-ALIX	200 µg/µl	1/1000	ALIX	S STB-EV	Cell Signalling
Anti- Cytochrome C	200 µg/µl	1/500	Cytochrome C	Placenta homogenate	Santa Cruz Biotechnology
Polyclonal mouse/rabbit immunoglobulin HRP	goat-anti-	1/2000	Mouse and Rabbit Immunoglobulins	N/A	Dako UK Ltd

788

789

790 **RNA-Sequencing Library Preparation and Sequencing**

791 For placental biopsy, 30 milligrams of placenta tissue were mechanically homogenized, and the
792 RNA extracted with the RNeasy kit. An equal amount of STB-EV (200 µg) was diluted up to
793 200 µl. Total RNA was then extracted from this STB-EV mixture with the miRCURY™ RNA
794 isolation kit. The extracted RNA was assessed for purity with Nanodrop (NanoDrop 1000
795 Software). After confirming that all samples had a 260/280 ratio greater than 1.8, the samples
796 were sent to the Wellcome Centre for Human Genetics (WCHG) for sequencing. At WCHG, the
797 RNA was assessed with a Bioanalyzer (Agilent Technologies) to determine the concentration

798 and RIN values (for PL) which were all greater than 8 except the STB-EV samples with RIN
799 between 1-3. It is widely accepted that the RIN values are not applicable for extracellular
800 vesicles due to 1) the fragmented nature of RNA they contain and the limited presence of 18S
801 and 28S ribosomal RNA peaks.

802 RNA libraries were prepared using the TruSeq RNA library preparation and small RNA library
803 preparation kits (Illumina). A standard procedure was followed for mRNA sequencing. Briefly,
804 polyadenylated mRNAs were selected from total RNA samples using oligo-dT-conjugated
805 magnetic beads. Poly-adenylated RNA samples were immediately converted into stranded
806 Illumina sequencing libraries using 200 bp fragmentation and sequential adapter following the
807 manufacturer's specifications. The resulting cDNA was amplified, enriched, and indexed using
808 12 cycles of amplification with PCR primers, including an index sequence to allow for
809 multiplexing. All RNA sequences were purified on gels and sequenced on a HiSeq2500 high
810 output v3 flow cell using paired-end, 75 bp reads (Illumina).

811

812

813

814

815

816

817

818

819

820

821

822 **Taqman Gene expression assays**

823 **Table S2.** Table showing qPCR Primers, assay ID and amplicon length.

Gene Symbol	Assay ID	Amplicon Length
PAPP-A2	Hs00535718_m1	67
INHBA	Hs01081598_m1	61
SIGLEC6	Hs00971272_g1	117
HTRA4	Hs00538137_m1	75
EBI3	Hs01057148_m1	64
FSTL3	Hs00610505_m1	84
HSD17B1	Hs00166219_g1	124
CGB3	Hs00361224_gh	55
YWHAZ	Hs01122445_g1	62
LEP	Hs00174877_m1	74
COL17A1	Hs00990036_m1	57
FLNB	Hs00963202_m1	100
SLC45A4	Hs01088148_m1	70

824

825

826

827

828


829 **Supplementary results**

830 **Table S3.** General characteristics of the STB-EV qPCR validation study population

Characteristics	Normal Pregnancy	Preeclampsia	P Value
Sample size	6	6	
Maternal age years (mean (SD))	35.50 (4.80)	37.25 (4.11)	0.600
Body mass index kg/m ² (mean (SD))	24.25(3.30)	34.88 (12.28)	0.146
Systolic blood pressure mmHg (mean (SD))	109.50 (6.86)	183.75 (12.87)	<0.001
Diastolic blood pressure mmHg (mean (SD))	76.00 (1.41)	113.25 (9.71)	<0.001
Proteinuria plus(es) (mean (SD))	0	3.00 (0.82)	<0.001
Gestational age at delivery in weeks (mean (SD))	39.50 (0.58)	33.50 (3.00)	0.008
Birth weight (grams) (mean (SD))	3627.50(247.98)	1808.75(488.54)	0.001
Intrauterine growth restriction (IUGR) = Yes (%)	0 (0)	4(100.00)	0.034
Male new-born gender (%)	2 (50.00)	1 (25.00)	1.000

831


832



833
834 **Figure S3.** Volcano plot showing differentially expressed genes in the placenta. The most
835 significantly upregulated genes are displayed in red on the right while the most significantly
836 downregulated genes are displayed in red on the left.

837

838



851 **Table S4.** List of overlapping gene ontology (GO) terms and KEGG Pathways in the placenta,
 852 medium/large STB-EVs and small STB-EVs

Sample Type	Gene Ontology terms and KEGG Pathway(s)
Biological Process (BP)	
Placenta and sSTB-EVs	Extracellular matrix organization Extracellular structure organization Cell-substrate adhesion Regulation of vasculature development Regulation of cell-substrate adhesion Positive regulation of vasculature development Cell-substrate junction assembly Cell-matrix adhesion Cell-substrate junction organization Positive regulation of angiogenesis Regulation of cell-matrix adhesion Positive regulation of cell adhesion Regulation of cellular response to growth factor stimulus Negative regulation of locomotion Endocrine process Negative regulation of cell-matrix adhesion Regulation of endocrine process Transmembrane receptor protein serine/threonine kinase signalling pathway Positive regulation of phosphatidylinositol 3-kinase signalling Regulation of transmembrane receptor protein serine/threonine kinase signalling pathway Endocrine hormone secretion Response to transforming growth factor beta Cellular response to transforming growth factor beta stimulus Response to decreased oxygen levels, Negative regulation of myeloid leukocyte differentiation Regulation of phosphatidylinositol 3-kinase signalling Response to hypoxia Response to oxygen levels Maintenance of location Regulation of gonadotropin secretion NAD metabolic process Lipid localization
Placenta and m/ISTB-EVs	Platelet degranulation
Molecular Function (MF)	
Placenta and sSTB-EVs	Cell adhesion molecule binding, Integrin binding
Cellular Component (CC)	
Placenta and sSTB-EVs	Collagen-containing extracellular matrix Leading-edge membrane Ruffle membrane Cell-cell junction
m/ISTB-EVs and sSTB-EVs	Vesicle lumen
Placenta, m/l STB-EVs and sSTB-EVs	Actin cytoskeleton Cytoplasmic vesicle lumen Secretory granule lumen Focal adhesion Cell-substrate junction

	Contractile fibre
Placenta and m/ISTB-EVs	Platelet alpha granule lumen
KEGG Pathways	
Placenta and sSTB-EVs	ECM-receptor interaction
	Inflammatory mediator regulation of TRP channels
	HIF-1 signalling pathway
	Glycolysis/gluconeogenesis
	Central carbon metabolism in cancer
	Proteoglycans in cancer
Placenta, m/ISTB-EVs and sSTB-EVs	Focal adhesion

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867